These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 16998723

  • 21. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Portaccio E, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Iaffaldano P, Direnzo V, D'Onghia M, Lepore V, Livrea P, Comi G, Amato MP, Italian Multiple Sclerosis Database Network Group.
    J Neurol Sci; 2009 Nov 15; 286(1-2):109-13. PubMed ID: 19615696
    [Abstract] [Full Text] [Related]

  • 22. Interferon-beta1b for multiple sclerosis.
    Burks J.
    Expert Rev Neurother; 2005 Mar 15; 5(2):153-64. PubMed ID: 15853486
    [Abstract] [Full Text] [Related]

  • 23. Is there or is there not a place for anti-interferon antibodies in the decision making of multiple sclerosis treatment optimisation?
    Grigoriadis N, Deretzi G, Artemis N, Tascos N, Milonas I.
    Neurol Sci; 2006 Sep 15; 27 Suppl 5():S355-7. PubMed ID: 16998719
    [Abstract] [Full Text] [Related]

  • 24. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
    Deisenhammer F, Schellekens H, Bertolotto A.
    J Neurol; 2004 Jun 15; 251 Suppl 2():II31-9. PubMed ID: 15264110
    [Abstract] [Full Text] [Related]

  • 25. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta.
    Lundkvist M, Greiner E, Hillert J, Fogdell-Hahn A.
    Mult Scler; 2010 Jul 15; 16(7):796-800. PubMed ID: 20534645
    [Abstract] [Full Text] [Related]

  • 26. Long-term follow-up of clinical trials of multiple sclerosis therapies.
    Freedman MS.
    Neurology; 2011 Jan 04; 76(1 Suppl 1):S26-34. PubMed ID: 21205679
    [Abstract] [Full Text] [Related]

  • 27. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
    Millonig A, Rudzki D, Hölzl M, Ehling R, Gneiss C, Künz B, Berger T, Reindl M, Deisenhammer F.
    Mult Scler; 2009 Aug 04; 15(8):977-83. PubMed ID: 19465447
    [Abstract] [Full Text] [Related]

  • 28. Interferon-beta for multiple sclerosis: Long-term benefits?
    Rudick RA, Cutter G.
    Ann Neurol; 2007 Apr 04; 61(4):283-5. PubMed ID: 17444503
    [No Abstract] [Full Text] [Related]

  • 29. Adherence to interferon-beta treatment and results of therapy switching.
    Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L.
    J Neurol Sci; 2007 Aug 15; 259(1-2):104-8. PubMed ID: 17376486
    [Abstract] [Full Text] [Related]

  • 30. Implications of neutralising antibodies on therapeutic efficacy.
    Bertolotto A.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S29-32. PubMed ID: 19200862
    [Abstract] [Full Text] [Related]

  • 31. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C, Gibassier J, de Seze J, Debouverie M, Moreau T, Pelletier J, Vermersch P, Edan G.
    Clin Chim Acta; 2008 May 01; 391(1-2):98-101. PubMed ID: 18249193
    [Abstract] [Full Text] [Related]

  • 32. Therapy of MS.
    Vosoughi R, Freedman MS.
    Clin Neurol Neurosurg; 2010 Jun 01; 112(5):365-85. PubMed ID: 20362388
    [Abstract] [Full Text] [Related]

  • 33. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
    Twork S, Nippert I, Scherer P, Haas J, Pöhlau D, Kugler J.
    Curr Med Res Opin; 2007 Jun 01; 23(6):1209-15. PubMed ID: 17559722
    [Abstract] [Full Text] [Related]

  • 34. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.
    Malucchi S, Capobianco M, Gilli F, Marnetto F, Caldano M, Sala A, Bertolotto A.
    Neurol Sci; 2005 Dec 01; 26 Suppl 4():S213-4. PubMed ID: 16388361
    [Abstract] [Full Text] [Related]

  • 35. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May 01; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 36. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.
    Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Di Sapio A, Capobianco M, Bertolotto A.
    J Neuroimmunol; 2005 Jan 01; 158(1-2):195-203. PubMed ID: 15589054
    [Abstract] [Full Text] [Related]

  • 37. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G.
    Clin Ther; 2009 Jun 01; 31(6):1142-57. PubMed ID: 19695384
    [Abstract] [Full Text] [Related]

  • 38. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 39. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
    Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS.
    Lancet Neurol; 2010 Jul 26; 9(7):740-50. PubMed ID: 20610349
    [Abstract] [Full Text] [Related]

  • 40. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
    Hurwitz BJ.
    J Neurol Sci; 2008 Sep 15; 272(1-2):8-19. PubMed ID: 18620708
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.